Intuitive Surgical stock edges higher on EU da Vinci SP approval and solid Q2 growth

Published on 09/18/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock closed at USD 383.54 on Nasdaq on September 17, 2026, after new EU approval for its da Vinci SP system in gynecologic surgery. Second quarter 2026 revenue and procedure growth underline the robotic specialist’s momentum.

Börseneditorialbild mit Händlern in Businesskleidung vor großen digitalen Displays mit aufwärts gerichteten Kerzencharts des Medizintechniksektors, warmes Bernsteinlicht des Handelssaals — Intuitive Surgical US46120E6023 Börseneditorial zeigt NASDAQ Medizintechnik Wachstumschart mit Händlern im Handelssaal, Illustration mit AI erstellt.

Intuitive Surgical stock (ISIN US46120E6023) closed at USD 383.54 on Nasdaq on September 17, 2026, up 0.33 percent from the prior close, as investors digested fresh European approval for its da Vinci SP system and the company’s latest growth figures.

New EU approval supports da Vinci SP growth

According to Zacks on September 18, 2026, Intuitive Surgical recently announced that its da Vinci SP single-port robotic system received CE mark approval in Europe for transvaginal gynecologic procedures, expanding the platform’s approved indications in the region.

Zacks notes that the new CE mark builds on existing approvals for the da Vinci SP system and opens an additional transvaginal route for gynecologic surgery, which should help the company deepen its presence in minimally invasive women’s health procedures.

Q2 2026 fundamentals and procedure trends

Per its latest quarterly update for the second quarter of 2026, Intuitive Surgical reported year-on-year increases in revenue and da Vinci procedure volume, underscoring that the business is still expanding even as the stock has corrected from earlier highs; these Q2 2026 figures represent the most recent interim reporting period and provide the fundamental backdrop for the current share price.

Intuitive Surgical has also highlighted continued growth in installed da Vinci systems and recurring revenue from instruments and accessories in Q2 2026, strengthening the argument that the razor-and-blades model remains intact and that procedure growth is translating into higher sales across its ecosystem.

Analyst stance and valuation signal

According to MarketBeat as of September 17, 2026, Intuitive Surgical stock carries a consensus rating of Moderate Buy with an average price target of USD 508.68, implying upside of about 32.6 percent versus the closing price of USD 383.54.

Based on data compiled by MarketBeat, Intuitive Surgical ended 2025 at a higher level and its shares are down by 32.3 percent so far in 2026, a performance that contrasts with the company’s ongoing growth in robotic procedures and offers a valuation entry point according to the prevailing analyst consensus.

Insider transaction and risk perspective

As InsiderTrades reported on September 17, 2026, Intuitive Surgical vice president Fredrik Widman sold 1,089 shares at an average price of USD 374.44 under a Rule 10b5-1 plan, a transaction worth about USD 407,765, leaving him with 1,026 shares.

According to InsiderTrades, institutional investors hold roughly 83.6 percent of Intuitive Surgical shares, and the stock carries an average analyst price target of USD 508.68 alongside a Moderate Buy rating, highlighting both strong professional ownership and a broadly positive stance despite insider selling.

Stock level and market data

Per the Nasdaq-based quote overview on MarketBeat, Intuitive Surgical stock closed at USD 383.54 on Nasdaq on September 17, 2026, with a prior close of around USD 382.29, corresponding to a daily gain of approximately 0.33 percent.

The same MarketBeat overview shows that Intuitive Surgical shares have fallen by 32.3 percent year to date in 2026 from a starting level of USD 566.36, a decline that contrasts with the company’s ongoing growth and leaves the stock trading below typical analyst valuation benchmarks.